Tau proteins are normal proteins found in nerve cells, where they help support the internal structure of neurons. They have become particularly important in medical research because abnormal tau changes and aggregates are a major feature of Alzheimer’s disease and several other neurodegenerative disorders.
That distinction matters: tau itself is not a disease. The concern is what can happen when tau becomes abnormally modified, misfolded or aggregated.
Modern research has also made tau more relevant to diagnosis. Certain forms of phosphorylated tau, including p-tau217 and p-tau181, can be measured using biological samples and are being used as biomarkers of Alzheimer’s-related pathology. However, a biomarker result should not be interpreted as a diagnosis without appropriate clinical context.
Quick Answer
Tau is a microtubule-associated protein that helps maintain the structure and function of neurons. In Alzheimer’s disease and other tauopathies, abnormal tau can accumulate inside neurons and form neurofibrillary tangles.
Some forms of phosphorylated tau can now be measured in blood and cerebrospinal fluid, and tau-related biomarkers are becoming increasingly important in Alzheimer’s assessment. They do not mean that every person with an abnormal tau result has the same disease or clinical outlook. Interpretation requires appropriate medical evaluation.
What Are Tau Proteins?
Tau proteins are part of a group of proteins associated with microtubules.
Microtubules are microscopic structures that form part of a cell’s internal framework. In neurons, they help support the cell and participate in transporting materials within nerve cells.
Tau interacts with these structures and contributes to their organization and stability. Researchers therefore describe tau as a microtubule-associated protein.
Tau is particularly important in neurons because these cells can have very long projections. Maintaining their internal transport system is essential for normal cellular function.
So the first important point is simple:
Normal tau is a functional protein, not a toxin.
What Happens to Tau in Alzheimer’s Disease?
In Alzheimer’s disease, tau undergoes abnormal biochemical changes.
One important process involves phosphorylation, in which phosphate groups are added to proteins. Tau is normally phosphorylated to some degree, but abnormal phosphorylation and other molecular changes can alter how tau behaves.
Pathological tau can detach from microtubules and become prone to aggregation. Over time, abnormal tau can form structures known as neurofibrillary tangles inside neurons. These changes are a defining feature of Alzheimer’s pathology.
Researchers continue to investigate exactly how tau changes contribute to neuronal dysfunction and death. Tau pathology is important, but Alzheimer’s disease is biologically complex and cannot be reduced to a single protein.
What Are Tau Tangles?
Tau tangles are abnormal accumulations of tau inside nerve cells.
They are also called neurofibrillary tangles.
In Alzheimer’s disease, abnormal tau becomes increasingly altered and aggregates into filamentous structures. These changes interfere with normal neuronal function and are associated with neurodegeneration.
Tau tangles are not unique to every case of dementia, however. Abnormal tau accumulation is also involved in a broader group of conditions known as tauopathies.
This is why the phrase “tau protein equals Alzheimer’s” is too simplistic.
What Is Phosphorylated Tau?
Phosphorylated tau, often abbreviated as p-tau, refers to tau that has phosphate groups attached to specific sites.
Researchers have found that certain forms of p-tau are particularly useful as biomarkers of Alzheimer’s-related brain changes.
Two forms that have received substantial attention are:
- p-tau181
- p-tau217
NIH-funded research has reported that these biomarkers can help identify Alzheimer’s-related pathology, with p-tau217 showing particularly strong promise.
The important point is that p-tau is a biomarker, not a diagnosis by itself.
Can Tau Be Measured in a Blood Test?
Yes.
Advances in highly sensitive laboratory methods have made it possible to measure certain tau-related biomarkers in blood.
This is important because traditional methods for investigating Alzheimer’s pathology can include cerebrospinal-fluid testing or specialized brain imaging. Blood-based biomarkers may provide a less invasive way of obtaining information about disease-related biological changes.
In May 2025, the U.S. Food and Drug Administration cleared the first blood-based diagnostic test intended to aid in diagnosing Alzheimer’s disease. The test measures a plasma ratio involving p-tau217 and amyloid-beta 1-42 and is intended for a defined population of adults aged 55 and older who have signs and symptoms consistent with the disease.
That does not mean every person can order a tau blood test and independently determine whether they have Alzheimer’s.
Testing and interpretation depend on the clinical situation, the specific assay and the healthcare system in which testing is performed.
Does a High Tau Result Mean Alzheimer’s Disease?
Not necessarily.
Tau biomarkers can provide important information about biological changes associated with Alzheimer’s, but medical diagnosis involves more than a laboratory number.
A healthcare professional may consider:
- symptoms and their progression;
- medical and family history;
- cognitive assessment;
- physical and neurological examination;
- medications and other health conditions;
- laboratory testing;
- brain imaging;
- cerebrospinal-fluid biomarkers;
- blood-based biomarkers where appropriate.
The National Institute on Aging notes that cerebrospinal-fluid testing can measure amyloid and tau-related biomarkers, while blood-based biomarkers are increasingly being developed and evaluated.
Therefore, a result should be interpreted in context rather than treated as a standalone prediction.
Tau Beyond Alzheimer’s Disease
Abnormal tau is associated with a broader group of neurological disorders called tauopathies.
These include Alzheimer’s disease and several other neurodegenerative conditions in which abnormal tau accumulation plays an important role.
The biological pattern of tau pathology can differ between diseases. Researchers study differences in tau structure, modification, location and aggregation to better understand these conditions.
This is another reason why “high tau equals Alzheimer’s” is an oversimplification.
Can Diet or Lifestyle Reduce Tau?
This is where readers should be especially cautious.
There is ongoing research into whether lifestyle factors influence brain aging, cognitive decline and the biological processes associated with neurodegenerative disease.
However, there is currently no specific food proven to remove tau tangles from the human brain.
The National Institute on Aging notes that research is investigating dietary patterns and individual foods in relation to Alzheimer’s disease, but evidence is not sufficient to claim that a particular food prevents Alzheimer’s or clears tau pathology.
Similarly, a laboratory finding involving a compound and tau should not automatically be translated into a recommendation to consume a food or supplement as a treatment.
For general brain health, a broader approach is more evidence-informed.
The World Health Organization’s 2026 dementia-risk-reduction guidance emphasizes measures such as regular physical activity, healthy eating, avoiding tobacco, reducing harmful alcohol use, managing conditions such as hypertension and diabetes, maintaining social and cognitive engagement, and addressing hearing problems where appropriate.
These measures are about overall brain and cardiovascular health. They should not be described as proven methods for removing tau.
Tau vs Amyloid: What Is the Difference?
Tau and amyloid are different proteins involved in Alzheimer’s disease.
Amyloid-beta can accumulate outside neurons and form plaques.
Tau is a protein associated with neurons and, in Alzheimer’s disease, can become abnormally modified and form intracellular neurofibrillary tangles.
Both are important parts of Alzheimer’s biology, but neither provides a complete explanation of the disease by itself.
This distinction is increasingly important because some modern biomarker tests assess combinations of amyloid- and tau-related markers rather than relying on one biological measurement.
When Should Someone Discuss Cognitive Symptoms With a Healthcare Professional?
Tau testing should not replace evaluation of actual symptoms.
Consider discussing persistent or worsening cognitive changes with a healthcare professional if they begin to affect:
- remembering recently learned information;
- managing money or medicines;
- completing familiar tasks;
- navigating familiar places;
- communication;
- judgment;
- work or daily independence.
Dementia is not a normal and inevitable part of ageing, although age is an important risk factor. WHO recommends a broad approach to reducing modifiable dementia risk across the life course.
A sudden change in mental status is different from gradual memory decline and can require urgent medical assessment, particularly when accompanied by neurological symptoms such as sudden weakness, difficulty speaking, loss of consciousness or severe unusual headache.
Practical Takeaway
Tau proteins are normal components of neurons. Their importance in medicine comes from what happens when tau becomes abnormally modified and accumulates in neurodegenerative diseases.
The most useful facts to remember are:
- Normal tau has important cellular functions.
- Abnormal tau aggregation is a major feature of Alzheimer’s disease and other tauopathies.
- Phosphorylated tau is increasingly useful as a biomarker.
- Blood-based tau testing is an important area of modern Alzheimer’s research and clinical development.
- A biomarker result should not be interpreted without appropriate clinical context.
- No food or supplement has been established as a way to remove pathological tau from the human brain.
- General brain-health measures remain more useful than chasing “tau-clearing” foods or supplements.
If you are concerned about persistent memory or thinking changes, the appropriate next step is a healthcare assessment—not trying to interpret tau biology from symptoms or internet information alone.
Key sources: WHO dementia guidance; National Institute on Aging; National Institute of Neurological Disorders and Stroke; U.S. FDA; peer-reviewed research indexed in PubMed.
Evidence limitation: Tau biology and biomarkers are advancing rapidly. The availability and interpretation of specific blood tests can differ between countries, laboratories and clinical settings.
FAQ
What are tau proteins?
Tau proteins are neuronal proteins that interact with microtubules and help support the internal structure and transport systems of nerve cells. Abnormal tau changes are associated with several neurodegenerative diseases.
Is tau protein normally present in the brain?
Yes. Tau is a normal protein found in neurons. It becomes medically concerning when it undergoes pathological changes and aggregation.
What are tau tangles?
Tau tangles, or neurofibrillary tangles, are abnormal accumulations of tau inside neurons. They are a characteristic feature of Alzheimer’s disease and other tauopathies.
What is p-tau217?
p-tau217 is a phosphorylated form of tau that has emerged as an important biomarker for Alzheimer’s-related pathology. Research suggests it can provide useful information about Alzheimer’s biology, but interpretation remains clinical rather than purely numerical.
Can tau be measured with a blood test?
Yes. Certain tau-related biomarkers can be measured in blood. In 2025, the FDA cleared a blood-based p-tau217/amyloid test to aid Alzheimer’s diagnosis in a defined symptomatic adult population.
Does high tau automatically mean Alzheimer’s?
No. Tau-related findings need to be interpreted alongside symptoms, clinical assessment and other relevant biomarkers or investigations.
Can food reduce tau protein?
There is not enough human clinical evidence to recommend a particular food as a way to remove pathological tau or treat Alzheimer’s disease. Research into diet and brain health continues.
Is tau involved in diseases other than Alzheimer’s?
Yes. Abnormal tau accumulation is associated with several neurodegenerative disorders collectively referred to as tauopathies.
MEDICAL DISCLAIMER
This article is for general health education and explains current knowledge about tau proteins, neurodegenerative disease and biomarkers. It does not diagnose Alzheimer’s disease, dementia or any other neurological condition.
A tau, p-tau or other biomarker result should not be interpreted independently or used to make personal treatment decisions. Testing and diagnosis should be discussed with an appropriately qualified healthcare professional.
Do not start, stop or change medicines or supplements based solely on this article.
Sudden confusion or sudden neurological symptoms require prompt medical assessment.
